Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma
Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
EDP Sciences
2021-01-01
|
| Series: | 4 open |
| Subjects: | |
| Online Access: | https://www.4open-sciences.org/articles/fopen/full_html/2021/01/fopen210003/fopen210003.html |
| _version_ | 1818920998241566720 |
|---|---|
| author | Blackstock Arthur W. Benson Al B. Kudo Masatoshi Jimenez Hugo Achari Preeya F. McGrath Callum Kirchner Volker Wagner Lynne I. O’Connell Nathaniel S. Walker Kathy Pasche Valerie K. D’Agostino Ralph Barbault Alexandre Pasche Boris |
| author_facet | Blackstock Arthur W. Benson Al B. Kudo Masatoshi Jimenez Hugo Achari Preeya F. McGrath Callum Kirchner Volker Wagner Lynne I. O’Connell Nathaniel S. Walker Kathy Pasche Valerie K. D’Agostino Ralph Barbault Alexandre Pasche Boris |
| author_sort | Blackstock Arthur W. |
| collection | DOAJ |
| description | Importance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue results in systemic delivery of low and safe levels of RF EMF from head to toe.
Objective: To report treatment outcomes and adverse events associated with treatment with the TheraBionic P1 device in comparison to suitable historical placebo and actively treated controls.
Design: Pooled case series with comparison to historical controls.
Participants: Patients with advanced HCC receiving this treatment, 18 real-world patients and 41 patients from a previously reported phase II study. Historical controls from previously conducted clinical trials.
Interventions: Three hours daily treatment with the TheraBionic P1 device compared with standard of care as received by historical controls in the previously conducted trials.
Main outcomes and measures: Overall survival (OS), time to progression, response rate, and adverse events in the combined pooled patients and in appropriate subgroups comparable to the historical control groups.
Results: In the pooled treatment group, median OS of patients with Child-Pugh A disease (n = 32) was 10.36 (95% CI 5.42–14.07) months, 4.44 (95% CI 1.64–7.13) months for patients with Child-Pugh B disease (n = 25), and 1.99 (95% CI 0.76–3.22) months for patients with Child-Pugh C disease (n = 2). Median OS for Child-Pugh A patients was 2.62 (33.9%) months longer than the 7.74 months OS of comparable historical controls (p = 0.036). The 4.73 (95% CI 1.18–8.28) months median OS for Child-Pugh B patients receiving TheraBionic P1 device as first line therapy is slightly higher than the 4.6 months median OS of historical controls receiving Sorafenib as first line therapy. Only grade 1 mucositis and fatigue were reported by patients using the device, even among Child-Pugh B and C patients. No patients discontinued treatment because of adverse events.
Conclusions and Relevance: Treatment of advanced HCC with the TheraBionic P1 device is well tolerated, even in patients with severely impaired liver function, and results in improved overall survival compared to historical controls without any significant adverse events, even after many years of continuous treatment. This treatment modality appears to be well suited for patients who have failed or are intolerant to currently approved therapies. |
| first_indexed | 2024-12-20T01:30:39Z |
| format | Article |
| id | doaj.art-7770903bdd2f4472a49fdde8880ba310 |
| institution | Directory Open Access Journal |
| issn | 2557-0250 |
| language | English |
| last_indexed | 2024-12-20T01:30:39Z |
| publishDate | 2021-01-01 |
| publisher | EDP Sciences |
| record_format | Article |
| series | 4 open |
| spelling | doaj.art-7770903bdd2f4472a49fdde8880ba3102022-12-21T19:58:07ZengEDP Sciences4 open2557-02502021-01-014310.1051/fopen/2021003fopen210003Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinomaBlackstock Arthur W.Benson Al B.0Kudo Masatoshi1Jimenez HugoAchari Preeya F.McGrath CallumKirchner Volker2Wagner Lynne I.O’Connell Nathaniel S.Walker Kathy3Pasche Valerie K.4D’Agostino RalphBarbault Alexandre5Pasche BorisDivision of Hematology/Oncology, Northwestern Medical GroupDepartment of Gastroenterology and Hepatology, Kindai University Faculty of MedicineGenolier Cancer CenterWake Forest Baptist Comprehensive Cancer CenterTheraBionic Inc.TheraBionic GmbHImportance: Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. Despite the recent approval of several new agents, long-term disease control remains elusive for most patients. Administration of 27.12 MHz radiofrequency (RF) electromagnetic fields (EMF) by means of a spoon-shaped antenna (TheraBionic P1 device) placed on the anterior part of the tongue results in systemic delivery of low and safe levels of RF EMF from head to toe. Objective: To report treatment outcomes and adverse events associated with treatment with the TheraBionic P1 device in comparison to suitable historical placebo and actively treated controls. Design: Pooled case series with comparison to historical controls. Participants: Patients with advanced HCC receiving this treatment, 18 real-world patients and 41 patients from a previously reported phase II study. Historical controls from previously conducted clinical trials. Interventions: Three hours daily treatment with the TheraBionic P1 device compared with standard of care as received by historical controls in the previously conducted trials. Main outcomes and measures: Overall survival (OS), time to progression, response rate, and adverse events in the combined pooled patients and in appropriate subgroups comparable to the historical control groups. Results: In the pooled treatment group, median OS of patients with Child-Pugh A disease (n = 32) was 10.36 (95% CI 5.42–14.07) months, 4.44 (95% CI 1.64–7.13) months for patients with Child-Pugh B disease (n = 25), and 1.99 (95% CI 0.76–3.22) months for patients with Child-Pugh C disease (n = 2). Median OS for Child-Pugh A patients was 2.62 (33.9%) months longer than the 7.74 months OS of comparable historical controls (p = 0.036). The 4.73 (95% CI 1.18–8.28) months median OS for Child-Pugh B patients receiving TheraBionic P1 device as first line therapy is slightly higher than the 4.6 months median OS of historical controls receiving Sorafenib as first line therapy. Only grade 1 mucositis and fatigue were reported by patients using the device, even among Child-Pugh B and C patients. No patients discontinued treatment because of adverse events. Conclusions and Relevance: Treatment of advanced HCC with the TheraBionic P1 device is well tolerated, even in patients with severely impaired liver function, and results in improved overall survival compared to historical controls without any significant adverse events, even after many years of continuous treatment. This treatment modality appears to be well suited for patients who have failed or are intolerant to currently approved therapies.https://www.4open-sciences.org/articles/fopen/full_html/2021/01/fopen210003/fopen210003.htmltherabionichepatocellular carcinomaamplitude-modulatedradio frequencyelectromagnetic fieldssorafenibam rf emf |
| spellingShingle | Blackstock Arthur W. Benson Al B. Kudo Masatoshi Jimenez Hugo Achari Preeya F. McGrath Callum Kirchner Volker Wagner Lynne I. O’Connell Nathaniel S. Walker Kathy Pasche Valerie K. D’Agostino Ralph Barbault Alexandre Pasche Boris Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma 4 open therabionic hepatocellular carcinoma amplitude-modulated radio frequency electromagnetic fields sorafenib am rf emf |
| title | Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| title_full | Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| title_fullStr | Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| title_full_unstemmed | Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| title_short | Safety and Efficacy of amplitude-modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| title_sort | safety and efficacy of amplitude modulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma |
| topic | therabionic hepatocellular carcinoma amplitude-modulated radio frequency electromagnetic fields sorafenib am rf emf |
| url | https://www.4open-sciences.org/articles/fopen/full_html/2021/01/fopen210003/fopen210003.html |
| work_keys_str_mv | AT blackstockarthurw safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT bensonalb safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT kudomasatoshi safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT jimenezhugo safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT acharipreeyaf safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT mcgrathcallum safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT kirchnervolker safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT wagnerlynnei safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT oconnellnathaniels safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT walkerkathy safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT paschevaleriek safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT dagostinoralph safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT barbaultalexandre safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma AT pascheboris safetyandefficacyofamplitudemodulatedradiofrequencyelectromagneticfieldsinadvancedhepatocellularcarcinoma |